Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.
about
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials.Antibodies and Antibody Derivatives: New Partners in HIV Eradication StrategiesRandomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ARTEngineering multi-specific antibodies against HIV-1
P2860
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Basis and Statistical Design o ...... st-of-Concept Efficacy Trials.
@en
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention
@nl
type
label
Basis and Statistical Design o ...... st-of-Concept Efficacy Trials.
@en
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention
@nl
prefLabel
Basis and Statistical Design o ...... st-of-Concept Efficacy Trials.
@en
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention
@nl
P2093
P2860
P50
P356
P1476
Basis and Statistical Design o ...... st-of-Concept Efficacy Trials.
@en
P2093
Allan C deCamp
Carter Bentley
Craig A Magaret
David N Burns
Deborah J Donnell
Edmund Capparelli
James G Kublin
John Hural
Julie McElrath
P2860
P356
10.1515/SCID-2016-0001
P50
P577
2017-01-01T00:00:00Z